Evidence map›Paper›PMID 32191380›Full record

ArticleGenesis (New York, N.Y. : 2000)2020

Generation of an Fsp1 (fibroblast-specific protein 1)-Flpo transgenic mouse strain.

Victoire Cardot-Ruffino, Véronique Chauvet, Cassandre Caligaris, Adrien Bertrand-Chapel, Nicolas Chuvin, Roxane M Pommier, Ulrich Valcourt, David Vincent, Sylvie Martel, Sophie Aires and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Genesis (New York, N.Y. : 2000), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Victoire Cardot-RuffinoINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.ORCID 0000-0002-5595-187X
Véronique ChauvetINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Cassandre CaligarisINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Adrien Bertrand-ChapelINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Nicolas ChuvinINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Roxane M PommierINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Ulrich ValcourtINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
David VincentINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Sylvie MartelINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Sophie AiresINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Bastien KaniewskiINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Pierre DubusINSERM, Univ Bordeaux UMR1053 Bordeaux Research in Translational Oncology, Bordeaux, France.
Philippe CassierINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Stéphanie SentisINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Laurent BartholinINSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.ORCID 0000-0002-5637-3223
Université Claude Bernard Lyon 1 · FRUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombination systems represent a major breakthrough in the field of genetic model engineering. The Flp recombinases (Flp, Flpe, and Flpo) bind and cleave DNA Frt sites. We created a transgenic mouse strain ([Fsp1-Flpo]) expressing the Flpo recombinase in fibroblasts. This strain was obtained by random insertion inside mouse zygotes after pronuclear injection. Flpo expression was placed under the control of the promoter of Fsp1 (fibroblast-specific protein 1) gene, whose expression starts after gastrulation at Day 8.5 in cells of mesenchymal origin. We verified the correct expression and function of the Flpo enzyme by several ex vivo and in vivo approaches. The [Fsp1-Flpo] strain represents a genuine tool to further target the recombination of transgenes with Frt sites specifically in cells of mesenchymal origin or with a fibroblastic phenotype.

Indexed as

AnimalsCells, CulturedDNA NucleotidyltransferasesFibroblastsGastrulaGene TargetingHaCaT CellsHumansMiceMice, Inbred C57BLMice, TransgenicPromoter Regions, GeneticS100 Calcium-Binding Protein A4ZygoteDNA NucleotidyltransferasesFLP recombinaseS100a4 protein, mouseS100 Calcium-Binding Protein A4fibroblast, Fsp1Flpomicerecombinasetransgenic

Identifiers

PMID32191380
PMCPMC7317532
OpenAlexW3011781198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.